Patents Assigned to Lung Therapeutics, Inc.
  • Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
    Patent number: 11905336
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: February 20, 2024
    Assignee: Lung Therapeutics, Inc.
    Inventors: Dale Christensen, John J. Koleng
  • MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS
    Publication number: 20240018186
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 18, 2024
    Applicant: Lung Therapeutics, Inc.
    Inventors: Dale CHRISTENSEN, John J. KOLENG
  • Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
    Patent number: 11787838
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: October 17, 2023
    Assignee: Lung Therapeutics, Inc.
    Inventors: Dale Christensen, John J. Koleng
  • MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS
    Publication number: 20230212223
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 6, 2023
    Applicant: Lung Therapeutics, Inc.
    Inventors: Dale CHRISTENSEN, John J. KOLENG
  • MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND USES THEREOF
    Publication number: 20230159608
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of pulmonary hypertension, lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 25, 2023
    Applicant: Lung Therapeutics, Inc.
    Inventor: Brian WINDSOR
  • COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2)
    Publication number: 20220160814
    Abstract: Provided herein are compositions comprising caveolin-1 (Cav-1) peptides and methods of using said compositions to protect type 2 alveolar epithelial cells from injury- or disease-induced apoptosis as well as increase the expression of the ABCA3 and SpC proteins.
    Type: Application
    Filed: March 11, 2020
    Publication date: May 26, 2022
    Applicant: Lung Therapeutics, Inc.
    Inventors: Roxana WASNICK, Andreas GUENTHER
  • MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS
    Publication number: 20210347820
    Abstract: Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
    Type: Application
    Filed: September 10, 2019
    Publication date: November 11, 2021
    Applicant: Lung Therapeutics, Inc.
    Inventors: Dale CHRISTENSEN, John J. KOLENG